Resumen

GONZALO-SALADO, MH; GARCIA-SANCHEZ, S; SILVA-CUEVAS, M  y  GARCIA-LUQUE, A. Positive assessment of drugs: from September, October, November and December of 2021. Sanid. Mil. [online]. 2022, vol.78, n.1, pp.33-41.  Epub 19-Sep-2022. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712022000100007.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from September to December of 2021, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palabras clave : abrocitinib (Cibinqo®); amivantamab (Rybrevant®); anifrolumab (Saphnelo®); artesunato (Artesunato Amivas®); avacopan (Tavneos®); casirivimab/imdevimab (Ronapreve®); diroximel fumarato (Vumerity®); enfortumab vedotin (Padcev®); eptinezumab (Vyepti®); finerenona (Kerendia®); glucarpidasa (Voraxaze®); inebilizumab (Uplizna®); linzagolix colina (Yselty®); lonapegsomatropina (Lonapegsomatropin Ascendis Pharma®); pegcetacoplan (Aspaveli®); pralsetinib (Gavreto®); regdanvimab (Regkirona®); ripretinib (Qinlock®); risperidona (Okedi®); sacituzumab govitecan (Trodelvy®); semaglutida (Wegovy®); somatrogón (Ngenla®); sotorasib (Lumykras®); sotrovimab (Xevudy®); tecovirimat (Tecovirimat SIGA®); tepotinib (Tepmetko®); vacuna conjugada de polisacárido neumocócico adsorbido (Vaxneuvance®); vacuna conjugada de polisacáridos neumocócicos adsorbidos 20-valente (Apexxnar®); voxelotor (Oxbryta®); zanubrutinib (Brukinsa®).

        · resumen en Español     · texto en Español     · Español ( pdf )